Log in
A new family of antiviral agents, bicyclic nucleoside analogues (BCNAs), discovered in Cardiff University has led to a highly potent anti-VZV (shingles) molecule, FV-100. On a worldwide basis more than two million patients are affected by shingles annually. FV-100 has successfully completed Phase II clinical trials, showing it is safe, potent and effective and with clinical advantages over the current standard of care. FV-100 has received more than $30 million in R&D investment, generating patents and creating highly skilled jobs in the UK and the USA, with the parent company currently valued at $397 million. It will enter registration trials in late 2013.
We have formulated and executed an extensive public engagement and outreach programme based on our leading technical and scientific involvement in the Herschel Space Observatory, a €1 billion astronomical satellite which was launched in 2009 and operated until April 2013. Herschel observed the Universe at far-infrared and submillimetre wavelengths with three scientific instruments, one of which (SPIRE) was built by an international team led by the Cardiff Astronomy Instrumentation Group, and Cardiff astronomers have been at the forefront in scientific use of Herschel and SPIRE. The beneficiaries of our PR and outreach programme include schoolchildren teachers, the media and the general public. The programme has achieved high exposure and impact locally, nationally and internationally. It provides inspirational personal contact and up-to- date material and information which has stimulated widespread and continuing interest in Herschel and also helped to raise the profile of STEM subjects, ultimately benefiting the economy.
Economic impact is claimed through the growth of the biopharmaceutical spin-out company Q Chip Ltd. During the REF period, this has created 19 new jobs, £7.5M investment, a new Dutch subsidiary (Q Chip BV), and staged-payment, six figure contract sales to four major international pharmaceutical companies.
Q Chip has generated over £928K in contract sales from the pharmaceutical industry from 2008-2012, with further sales of over £1M projected in 2013-14.
Originally established by Professor David Barrow in 2003 from his micro technology research, Q Chip has developed new processes and miniaturised equipment to encapsulate materials, including drugs, within uniform polymeric microspheres as injectable therapeutics.
3D scanning technology has enabled multiple opportunities for innovation in diverse areas such as manufacturing, design, and the arts. However, full utilisation of this technology requires not just the scanning hardware, but accompanying software that can build meaningful, editable models. This development has been pioneered by research conducted in the School of Computer Science and Informatics, at Cardiff University. Innovative algorithms for reverse engineering and digital shape reconstruction were devised that enabled the reconstruction of complex computer aided design (CAD) models from data captured by 3D scanners. The algorithms have been endorsed by Geomagic Inc, a market leading American software corporation (recently acquired by 3D Systems), that has subsidiaries in Europe and Asia and global distributors, and incorporated into their software product suite. This is accessed by nearly 10,000 licensed users worldwide, who have applied the product for industrial applications including aerospace and automotive engineering, product design, cultural heritage preservation, and healthcare. Accordingly, the impacts claimed are twofold: a) economic gain manifesting in the benefits to Geomagic and a plethora of end users who have utilised the software, b) impact on practitioners and professional services in diverse domains.
Economic gains by oil and gas companies, improvements in professional practice in hydrocarbon exploration, and environmental benefits from identifying CO2 disposal sites have been achieved through a Cardiff-led consortium with industry. Building on research carried out since 2004, ten of the largest oil companies in the World have contributed to and benefited from understanding how faulted caprocks behave under specific geological conditions. Research at Cardiff has shown which families of faults and fractures make caprocks highly permeable, thus improving Industry's ability to predict if caprocks are able to prevent oil and gas reaching the surface.
Research and Development activity at Cardiff University's Astronomy Instrumentation Group (AIG) has been commercialised and made available to the international market. Sales have been made to fields including bio-molecular spectroscopy for health science, plasma fusion diagnostics for sustainable energy, and remote atmospheric sensing. This has resulted in economic impact through:
Loughborough University's (LU) research collaboration with The Hardstaff Group has resulted in a commercial Oil-Ignition-Gas-Injection system (OIGI®), which substitutes natural gas for Diesel oil in heavy goods vehicles. Using optical diagnostics OIGI® was redesigned, increasing average substitution rates from 45% to 60%. The economic impact for Hardstaff was a fuel saving of £406k per annum. The research allowed Hardstaff to create new business with Mercedes-Benz in the UK and Volvo in Sweden. OIGI® reduces CO2 by up to 15%, harmful nitrogen oxides and particulate emissions by 30%. The research also demonstrated, for the first time, dual fuel technology in small, high-speed diesel engines, paving the way for its application in passenger cars.
Cardiff University research in 1997-2008 resulted in the development of a family of novel far-red fluorescent dyes that stain the DNA of cells. The leading live cell dye DRAQ5™ is now utilised in a wide range of laboratory assays, transforming practice in clinical, commercial and research sectors. Smith co-founded the multi-award-winning start-up company Biostatus Ltd in 2001 to undertake product development. Commercial impact post-2008 has been the generation of over $3.2 million in sales revenue enabling job creation, direct funding of UK academic research positions and creation of new technology start-up companies. Used in over 3,500 research, pharmaceutical and clinical organisations, DRAQ™ technology has global reach.
Cardiff University research led to second-generation chemiluminescent technology. The invention allowed for internal amplification control in nucleic-acid based clinical diagnostic assays for infectious disease and produced results with greater accuracy and fulfilled previously unmet regulatory standards. Adopted by the market leader in nucleic acid diagnostics (a sub-licensee of Cardiff University) the Cardiff technology is used globally in more than 60 million in vitro diagnostic tests annually. Sales of the tests approach $500 million per year and the sub-licensee was subsequently sold for $3.8 billion.
Platinum Group Elements (PGE) are critical strategic metals because of their unrivalled applications in catalysts, fuel cells and electronics and cancer therapies. Research and analytical methods developed at Cardiff have impacted on exploration for new PGE deposits, and more efficient processing of PGE ores by international mining companies. A key milestone between 2009 and 2012 was the discovery of a 3 billion year old giant impact crater in West Greenland. This discovery is of major economic significance because all craters previously found in this size class are associated with multi-billion dollar mineral and/or hydrocarbon resources. It led to an intellectual property transaction worth CDN$ 2.1 million and discovery of nickel and PGE deposits in Greenland by North American Nickel Incorporated.